JP2021530498A5 - - Google Patents

Info

Publication number
JP2021530498A5
JP2021530498A5 JP2021500858A JP2021500858A JP2021530498A5 JP 2021530498 A5 JP2021530498 A5 JP 2021530498A5 JP 2021500858 A JP2021500858 A JP 2021500858A JP 2021500858 A JP2021500858 A JP 2021500858A JP 2021530498 A5 JP2021530498 A5 JP 2021530498A5
Authority
JP
Japan
Prior art keywords
domain
igg1
domain monomer
monomer
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041468 external-priority patent/WO2020014526A2/en
Publication of JP2021530498A publication Critical patent/JP2021530498A/ja
Publication of JP2021530498A5 publication Critical patent/JP2021530498A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500858A 2018-07-11 2019-07-11 ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021530498A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696759P 2018-07-11 2018-07-11
US62/696,759 2018-07-11
US201862733036P 2018-09-18 2018-09-18
US62/733,036 2018-09-18
US201862744067P 2018-10-10 2018-10-10
US62/744,067 2018-10-10
PCT/US2019/041468 WO2020014526A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Publications (2)

Publication Number Publication Date
JP2021530498A JP2021530498A (ja) 2021-11-11
JP2021530498A5 true JP2021530498A5 (https=) 2022-07-15

Family

ID=69141927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500858A Withdrawn JP2021530498A (ja) 2018-07-11 2019-07-11 ＣＤ３８を標的とする改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20210269546A1 (https=)
EP (1) EP3820516A4 (https=)
JP (1) JP2021530498A (https=)
KR (1) KR20210044218A (https=)
CN (1) CN113194990A (https=)
AU (1) AU2019299973A1 (https=)
BR (1) BR112021000416A2 (https=)
CA (1) CA3106142A1 (https=)
IL (1) IL280046A (https=)
MX (1) MX2021000307A (https=)
WO (1) WO2020014526A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN118251411A (zh) * 2021-09-29 2024-06-25 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN115873127B (zh) * 2021-11-26 2026-04-10 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
IL313617A (en) * 2021-12-17 2024-08-01 Modex Therapeutics Inc Antigen-binding polypeptide complexes containing extracellular regions of TNFSF ligands
WO2025229160A1 (en) * 2024-05-01 2025-11-06 Commit Biologics Aps Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CN107406506A (zh) * 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
WO2017025323A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
EP3423572B1 (en) * 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN110022898B (zh) * 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法

Similar Documents

Publication Publication Date Title
JP2021530498A5 (https=)
JP2021532085A5 (https=)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2020514301A5 (https=)
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
JP2020508655A5 (https=)
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
JP2021531268A5 (https=)
JP2022519118A5 (https=)
RU2007139953A (ru) Антитела к ccr5 и их применение
DE602004021702D1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
JP2017504578A5 (https=)
JP2021530989A5 (https=)
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
RU2018129878A (ru) Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
DK1697421T3 (da) Bispecifikke antistoffer
RU2016138347A (ru) Трифункциональная антигенсвязывающая молекула
NZ597168A (en) Dual variable domain immunoglobin and uses thereof
PL1752471T3 (pl) Syntetyczne domeny immunoglobulinowe o właściwościach wiążących konstruowanych w regionach cząsteczki różnych od regionów determinujących komplementarność
WO2007048037A3 (en) METHODS FOR GENERATING MONOVALENT IgG
JP2021531756A5 (https=)
MX2025010747A (es) Union de anticuerpos biespecificos al dominio similar a la proteasa del receptor transferrina humano htfr1